Does the girl in the picture below symbolise how you feel at this juncture? Do you also suffer from depression? You don't have to worry because there are several coping mechanisms available, such as taking antidepressants, to manage depression.
But, as they say, there are two sides to every coin. Antidepressant medications might also have side effects. About 8.6 million people were identified in 2022–2023 and given 86 million prescriptions for antidepressants in England, according to the NHS Business Services Authority (NHSBSA). It was a 2% increase, or 200,000 more patients, than in 2021–2022. The benefits of using the medications for an extended period aren't well proved by research.
Antidepressant medication is a part of drug therapy for clinical depression. It also provides treatment for plenty of other illnesses, including post-traumatic stress disorder (PTSD), generalised anxiety disorder (GAD), and obsessive-compulsive disorder (OCD). Various antidepressants have a wide range of potential side effects.
My article will explain specific side effects associated with different classes of antidepressants and provide concrete advice on how to minimise and manage them. Deep exploration of the nuances of antidepressant side effects continues, providing insightful information for thorough understanding.
Introduction
A critical condition that affects people of all ages worldwide is depression. In the past few decades, antidepressant prescription rates have skyrocketed in several countries as a means of treating depression. Antidepressant medication is one of the most often prescribed drug groups for young and middle-aged adults, according to statistics from the US, Canada, and the UK.
These drugs are similarly effective and available in a range of forms. As such, evaluating potential side effects is the primary factor that influences the choice of antidepressants. Despite the widespread use of antidepressants, there is relatively little information on their safety across a range of serious adverse outcomes in young and middle-aged adults.
Randomised controlled trials (RCT) assess adverse effects; however, they are often small-scale, short-term studies that involve a chosen set of participants. Antidepressant use makes it more difficult for elderly persons to drive, while there is conflicting data regarding younger drivers.
Studies have also linked the use of antidepressants to higher risks of gastrointestinal bleeding (GIB), adverse drug reactions, and all-cause mortality; however, there is insufficient data on young and middle-aged adults, whose patterns of risk may differ from those of older adults due to higher levels of comorbidity and increased susceptibility to side effects in older populations.1
Types of antidepressants
Several antidepressant classes appear in the table, along with their mechanisms of action and frequently prescribed drugs.
| Types | Mechanism of action | Commonly prescribed drugs |
| Selective Serotonin Reuptake Inhibitors (SSRIs) | The mechanism of 5-hydroxytryptamine/serotonin (5HT)-induced neurotransmission termination is neuronal absorption, mediated by the serotonin reuptake transporter (SERT) into presynaptic terminals. SSRIs both increase and extend serotonergic neurotransmission and prevent reuptake. Ongoing SSRI treatment increases the production of new neurons, phosphorylates nuclear transcription factors, increases cyclic adenosine monophosphate (AMP) signalling, and increases the expression of brain-derived neurotrophic factor (BDNF). SSRIs are currently the first-choice drugs for treating depression. | -Sertraline -Fluvoxamine -Fluoxetine -Paroxetine -Citalopram -Escitalopram |
| Serotonin and noradrenaline reuptake inhibitors (SNRIs) | SNRIs block serotonin and noradrenaline from being reabsorbed in synapses and increase postsynaptic receptor activation. | -Venlafaxine -Desvenlafaxine -Duloxetine -Milnacipran -Levomilnacipran |
| Atypical antidepressants | Bupropion prevents noradrenaline and dopamine from being reabsorbed at the presynaptic cleft. Agomelatine functions at the MT1 and MT2 melatonin receptors as an agonist. By inhibiting alpha-2 adrenergic receptors on nerve terminals and cell bodies, mirtazapine facilitates noradrenaline release into the synapses. | -Bupropion -Mirtazapine |
| Tricyclic antidepressants (TCAs) | By preventing noradrenaline and serotonin reuptake at the presynaptic neuronal membrane, TCA causes anticholinergic and sedative side effects. | -Amitriptyline -Clomipramine -Desipramine -Nortriptyline -Imipramine |
| Monoamine Oxidase Inhibitors (MAOIs) | MAOIs inhibit the monoamine oxidase (MAO) enzyme, which catabolises noradrenaline, serotonin, and dopamine. The first antidepressant ever produced, MAOI, was not acknowledged as the primary therapy for depression because of its side effects and risk for medication interactions. | -Selegiline transdermal patch -Isocarboxazid -Phenelzine2 |
Common side effects
Analysing the typical adverse effects of antidepressants offers insights into the possible difficulties patients may have while undergoing medication. The table shows the adverse effects caused by different antidepressants.
| Systems affected | Adverse effects | Antidepressant medications |
| Gastrointestinal | -Nausea -Diarrhoea -Constipation and dry mouth -Increased appetite, Anorexia, and weight gain -Irritable bowel syndrome (IBS) | Sertraline, fluvoxamine, venlafaxine, bupropion, duloxetine and MAOI Sertraline and fluvoxamine Paroxetine, venlafaxine, mirtazapine, duloxetine, and TCA Fluoxetine, mirtazapine and duloxetine, TCA and MAOI |
| Central nervous | -Insomnia, anxiety, irritability, nervousness, and restlessness -Dizziness and sedation -Headache, vivid dreams, night tremors, seizures -Blurred vision, narrow-angle glaucoma, and dilated pupils | SSRI, venlafaxine, and duloxetine Mirtazapine, TCA and MAOI SSRI and bupropion TCA and duloxetine |
| Cardiac | -Tachycardia and orthostatic hypotension -Hypertension and hypertensive crisis | TCA and MAOI Venlafaxine, duloxetine, and MAOI |
| Blood and electrolytes | Prolong bleeding and hyponatremiaNeutropenia | SSRI Mirtazapine |
| Reproductive | -Ejaculatory disturbances and decreased libido -Sexual dysfunction | SSRI Venlafaxine, duloxetine, TCA, and MAOI |
| Liver and endocrine | -Alanine aminotransferase (ALT) elevated -Pyridoxine deficiency and hepatotoxicity | Mirtazapine MAOI7 |
Serious side effects
A thorough grasp of the possible risks involved necessitates a review of the severe side effects mentioned below.
Suicidal thoughts and behaviour
The Food and Drug Administration (FDA) issued a Public Health Advisory in March 2004 that advised doctors to keep an eye on their patients and to remind them of the warning labels for ten commonly used antidepressants about rising depression and the beginning of suicidal thoughts.
Because there was a higher risk of suicidality in paediatric patients, the FDA required a black box warning for all antidepressant drugs in September 2004. To keep a closer eye out for the appearance of these side effects, it becomes sense to plan more regular follow-up appointments at the start of treatment.7,8
Serotonin syndrome (SS)
SS is a fatal adverse medication reaction characterised by an abnormal surge in serotonergic activity in both the central and peripheral nervous systems. It displays symptoms related to behavioural anomalies, neuromuscular excitability, and autonomic instability. Pentazocine, L-tryptophan, SSRI, and MAOI together may cause this condition. Therefore, due to the long half-life of fluoxetine, the patient should wait at least two weeks after quitting SSRI and at least five weeks if switching from fluoxetine.7,9
Allergic reactions
SSRIs can lead to photosensitivity, spontaneous bruising, pruritus, alopecia, and hives. Patients on SSRIs seldom experience severe cutaneous reactions, such as toxic epidermal necrosis, erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and drug-induced hypersensitivity reactions. Immediate medical attention is needed.10
Withdrawal symptoms
Twenty percent of those who take an antidepressant continuously for one month and then abruptly cease using it or drastically reduce their dosage are suffering from antidepressant discontinuation syndrome (ADS). The acronym FINISH summarises the withdrawal symptoms.
F- Flu-like symptoms, including lethargy, exhaustion, headache, achiness, and sweating
I- Insomnia, vivid dreams
N- Nausea, often with vomiting
I- Imbalance with lightheadedness, dizziness, and vertigo
S- Sensory disturbances
H- Hyperarousal (agitation, hostility, mania, jerkiness, and anxiety)
Patients should speak with their healthcare provider before quitting an antidepressant to reduce the chance of developing the condition.11
Managing side effects
Working together with medical professionals, patients, and clinicians can effectively manage side effects related to antidepressant treatment.
Patient education
Educating patients before starting antidepressants is a crucial part of managing side effects. Discussion involves a review of typical adverse effects and their likelihood of occurring. Communicate with patients which side effects are manageable (e.g., mild nausea or jitteriness) and which require immediate attention (e.g., rash, agitation, or increasing suicidal thoughts).
Lifestyle modifications
Sustaining a healthy lifestyle involves closely monitoring sleep habits and personal hygiene, consuming enough water and fibre, making dietary and physical activity modifications, and minimising caffeine and other stimulants.
Dosage adjustment
Finding a balance between the therapeutic and side effects may require adjusting the dosage. To reduce the chance of severe side effects, several factors need to be considered which include pharmacological management, dose reduction, and switching to an alternative antidepressant. Other steps that can be taken include switching the dosing schedule from morning to night time, dividing dosing or using a slower release preparation.
Combination therapy
Psychotherapy and cognitive behavioural therapy (CBT) are other effective strategies to increase patient adherence to medicine and to avoid adverse effects of antidepressant drugs.12
FAQs
What factors affect the selection of antidepressants?
Preventing particular adverse effects, having co-occurring mental illnesses, and having specific clinical symptoms were the most frequent criteria affecting antidepressant choice. The second most commonly mentioned factor influencing medication choice was prior treatment history, including earlier drug responses—whether successful or unsuccessful. Some concerns mentioned, such as anxiety over discontinuation syndrome and drug-drug interactions, rarely affect the choice of antidepressants.3
Is it possible to treat depression using complementary and alternative therapies?
Therapies from complementary and alternative medicine (CAM) augment conventional medical care. Examples of CAM include organic goods such as herbs and nutritional supplements (vitamins, minerals, and probiotics) combined with mind-body therapies such as yoga, acupuncture, tai chi, qi gong, chiropractic adjustments, relaxation techniques, and meditation. The practices of traditional healers from other continents, such as those from Asia (Ayurveda and traditional Chinese medicine (TCM) and Europe (homoeopathy and naturopathy), are also included in CAM.4
Is it safe to consume alcohol when taking antidepressants?
Because heavy drinking and depression overlap, there is concern that heavy drinking by depressed people may outweigh the benefits of antidepressant medications. Furthermore, certain antidepressant types may interact with alcohol or other drugs. However, even while some evidence suggests that antidepressants have a beneficial effect on assigned males at birth (AMAB) than on assigned females at birth (AFAB), new meta-analyses have indicated that antidepressants may help patients with combined depressive and substance use disorders by reducing their drinking.5
Is long-term use of antidepressants safe?
Short-term (acute and continuation phase for 4–12 months) and long-term (maintenance phase lasting one year to indefinitely) are the two categories for antidepressant use. The increase in antidepressant use has been attributed, in part, to longer-term treatments.
Although 30% of patients in this trial reported having moderate-to-severe depression while using antidepressants, the majority of patients felt that the drugs helped them feel less depressed and had a slightly better quality of life. In addition, 45 percent of patients thought they had an antidepressant addiction. Regular evaluations are essential for monitoring patient's health and preferences about continuing antidepressant medication while undergoing long-term treatment.6
Summary
Antidepressants are medications designed to alleviate symptoms of depression and offer hope for improved psychological health. Like any medication, they may also cause adverse effects. Through informed decision-making and ongoing communication with physicians, managing the side effects of antidepressants is possible.
To help people thinking about or currently using antidepressant medication, presenting a fair and impartial viewpoint with the knowledge they need to make informed decisions and advance their general well-being.
References
- Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in people aged 20–64: cohort study using a primary care database. BMC Medicine [Internet]. 2018 Mar 8 [cited 2024 Jan 22];16(1):36. Available from: https://doi.org/10.1186/s12916-018-1022-x
- Sheffler ZM, Patel P, Abdijadid S. Antidepressants. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2024 Jan 22]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK538182/
- Zimmerman M, Posternak M, Friedman M, Attiullah N, Baymiller S, Boland R, et al. Which factors influence psychiatrists’ selection of antidepressants? AJP [Internet]. 2004 Jul [cited 2024 Jan 22];161(7):1285–9. Available from: https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.161.7.1285
- Haller H, Anheyer D, Cramer H, Dobos G. Complementary therapies for clinical depression: an overview of systematic reviews. BMJ Open [Internet]. 2019 Aug 5 [cited 2024 Jan 22];9(8):e028527. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686993/
- Graham K, Massak A. Alcohol consumption and the use of antidepressants. CMAJ [Internet]. 2007 Feb 27 [cited 2024 Jan 22];176(5):633–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1800314/
- Cartwright C, Gibson K, Read J, Cowan O, Dehar T. Long-term antidepressant use: patient perspectives of benefits and adverse effects. Patient Prefer Adherence [Internet]. 2016 Jul 28 [cited 2024 Jan 22];10:1401–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970636/
- KHAWAM EA, LAURENCIC G, MALONE JR. DA. Side effects of antidepressants: An overview. Cleveland Clinic Journal of Medicine [Internet]. 2006 Apr [cited 2024 Jan 23]; Available from: https://www.ccjm.org/content/ccjom/73/4/351.full.pdf
- Reeves RR, Ladner ME. Antidepressant‐induced suicidality: an update. CNS Neurosci Ther [Internet]. 2010 Jun 11 [cited 2024 Jan 23];16(4):227–34. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493906/
- Poian LR, Chiavegatto S. Serotonin syndrome: the role of pharmacology in understanding its occurrence. Cureus [Internet]. [cited 2024 Jan 23];15(5):e38897. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257984/
- Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int [Internet]. 2021 Aug 5 [cited 2024 Jan 23];13(3):387–401. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395812/
- Gabriel M, Sharma V. Antidepressant discontinuation syndrome. CMAJ [Internet]. 2017 May 29 [cited 2024 Jan 23];189(21): E747. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449237/
- Kelly K, Posternak M, Jonathan EA. Toward achieving optimal response: understanding and managing antidepressant side effects. Dialogues Clin Neurosci [Internet]. 2008 Dec [cited 2024 Jan 23];10(4):409–18. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181894/

